US-based Immune Design has started dosing patients in a Phase I clinical study of LV305, an immuno-oncology investigational agent from...
Read moreOn Friday, June 06, 2014, the NASDAQ Composite ended at 4,321.40, up 0.59%, the Dow Jones Industrial Average finished the...
Read moreThere are 5 million persons suffering from asthma in Great Britain and despite medication, half a million of these persons...
Read moreUS-based biotechnology firm Edge Therapeutics has started enrolling patients in the second group of a multicenter, randomised, controlled, open-label, Phase...
Read moreUS-based Arena Pharmaceuticals has started dosing patients in an investigational Phase Ib clinical trial of APD334, an oral drug candidate...
Read moreAs of January 2014, the EMA lifted the restriction on providing fee reductions to large companies developing new orphan drugs...
Read moreProvence Technologies acquires SynprosisThe acquisition strengthens Provence Technologies’ expertise in its core business of therapeutic chemistry Provence Technologies Group, a...
Read moreUS-based Boston Therapeutics (BTI) has started a Phase IIb clinical trial SD-002 to evaluate the efficacy and safety of Sugardown...
Read moreThe Orphan Drugs Market is set to Rise as a Result of Pharma Companies now Looking to Orphan Drugs as...
Read morePolyplus-transfection SA, a privately-held company specializing in the development of innovative solutions for transfection, today announces the launch of FectoPRO(TM),...
Read more
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.
